In particular, dual anti‐targeted therapy with camrelizumab combined with bevacizumab has already been observed to have better efficacy in 18 months of treatment with no significant adverse effects, providing a new referenceable treatment option for patients with advanced NSCLC with KRAS mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.